Biolegend, 368515, APC/Cyanine7 anti-human CD45 Antibody, 25tests

CD45 is a 180 - 240 kD single chain type I membrane glycoprotein also known as leukocyte common antigen (LCA) and T200. It is a tyrosine phosphatase expressed on the plasma membrane of all hematopoietic cells, except erythrocytes or platelets. CD45 is a signaling molecule that regulates a variety of cellular processes including cell growth, differentiation, cell cycle, and oncogenic transformation. CD45 plays a critical role in T and B cell antigen receptor-mediated activation by dephosphorylating substrates including p56Lck, p59Fyn, and other Src family kinases. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to bind galectin-1 and to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4.
25tests
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Human PBMC
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography and conjugated with APC/Cyanine7 under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Red Laser (633 nm)
Application Notes: It was found that the HI30 clone and the 2D1 clone can cross block each other's binding.
Application References(PubMed link indicates BioLegend citation): Bradstock KF, et al. 1980. J. Natl. Cancer Inst. 65:33. Csiba A, et al. 1984. Br. J. Cancer 50:699. Tchilian EZ, et al. 2001. J. Immunol. 166:1308. Lee MS, et al. 2004. Int. Immunol. 16:1109.
Product Citations: Liu C, et al. 2021. Cell. 184(7):1836-1857.e22. PubMed Tian L, et al. 2022. Nat Cancer. 3:1318. PubMed Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed Antonyshyn JA, et al. 2022. Biomater Biosyst. 6:100049. PubMed Zhang AQ, et al. 2023. Nat Biomed Eng. . PubMed Healy LM, et al. 2020. Glia. 68:811. PubMed Ge W, et al. 2022. Int J Mol Sci. 24: . PubMed Vondra S, et al. 2023. Cell Rep. 42:111977. PubMed Calvanese V, et al. 2022. Nature. 604:534. PubMed Wang H, et al. 2022. Front Immunol. 13:852436. PubMed Chen M, et al. 2021. Cancers (Basel). 13:. PubMed Merugu S, et al. 2020. Methods Enzymol. 639:289. PubMed Philippeos C, et al. 2018. J Invest Dermatol. 138:811. PubMed Kou R, et al. 2018. Oncol Rep. 7:2013. PubMed Srideshikan SM, et al. 2019. Clin Cancer Res. 25:7463. PubMed Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed Dong Y, et al. 2020. J Leukoc Biol. 108:1711. PubMed Hasselmann J, et al. 2020. Neuron. 103(6):1016-1033. PubMed Jing Y, et al. 2020. Cancer Gene Ther. 27:910. PubMed Pandolfi J, et al. 2016. J Immunol. 196: 3287-3296. PubMed Hazenberg MD, et al. 2019. Blood Adv. 2.659722222. PubMed Shi X, et al. 2022. Clin Transl Med. 12:e711. PubMed Still C 2nd, et al. 2021. Cell Reports Medicine. 2(7):100343. PubMed Zhou WJ, et al. 2022. Sci Adv. 8:eabj2488. PubMed Voskamp C, et al. 2020. Front Bioeng Biotechnol. 0.790277778. PubMed Nowak W, et al. 2020. EBioMedicine. 50:290-305.. PubMed Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed Xi H, et al. 2020. Cell Stem Cell. 27(1):158-176. PubMed Zhou F, et al. 2018. Cancer Manag Res. 0.727083333. PubMed Hu J, et al. 2022. J Immunother Cancer. 10:. PubMed Ruan LY, et al. 2022. Biomolecules. 12:. PubMed Zhao Y, et al. 2020. Front Immunol. 2.572222222. PubMed Kwok I, et al. 2020. Immunity. 53(2):303-318.e5. PubMed Dou D, et al. 2016. Nat Cell Biol. 18: 595-606. PubMed Karlsson J, et al. 2020. Nat Commun. 1.773611111. PubMed Antonyshyn JA, et al. 2021. Commun Biol. 4:1205. PubMed Tan EE, et al. 2020. J Clin Invest. 130:5817. PubMed
RRID: AB_2566375 (BioLegend Cat. No. 368515) AB_2566376 (BioLegend Cat. No. 368516)
Structure: Type I transmembrane protein, 180 - 240 kD (multiple isoforms)
Distribution: Hematopoietic cells, except circulating erythrocytes or platelets.
Function: Tyrosine phosphatases, signaling, co-stimulation (co-inhibition), TCR and BCR mediated activation.
Ligand/Receptor: Galectin-1, CD2, CD3, and CD4.
Cell Type: B cells, Dendritic cells, Neutrophils
Biology Area: Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family: CD Molecules, Protein Kinases/Phosphatase, TCRs
Antigen References: 1. Thomas M. 1989. Annu. Rev. Immunol. 7:339. 2. Trowbridge I, et al. 1994. Annu. Rev. Immunol. 12:85.
Gene ID: 5788
UniProt: View information about CD45 on UniProt.org
Clone: 2D1
Regulatory Status: RUO
Other Names: Leukocyte Common Antigen (LCA), T200
Isotype: Mouse IgG1, κ